SciELO - Scientific Electronic Library Online

 
vol.146 issue12Gallbladder epidermoid carcinomaConsensus about the duties of pharmacists in intensive care units in Chile author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista médica de Chile

Print version ISSN 0034-9887

Abstract

FERNANDEZ-LAZARO, Diego; FERNANDEZ-LAZARO, César Ignacio; CABALLERO GARCIA, Alberto  and  CORDOVA MARTINEZ, Alfredo. Immunomodulator drugs for the treatment of multiple myeloma. Rev. méd. Chile [online]. 2018, vol.146, n.12, pp.1444-1451. ISSN 0034-9887.  http://dx.doi.org/10.4067/s0034-98872018001201444.

Thalidomide changed the treatment of patients with multiple myeloma, however, its effectiveness has been compromised due to its side effects. New strategies are needed to specifically target the challenges of multiple myeloma through innovative, more effective, and less toxic therapy. The new immunomodulatory (IMiDs) compounds are structural and functional analogs of thalidomide, which were designed to improve the immunomodulatory and anticancer properties and tolerability profiles. We review the development of second generation IMiDs, lenalidomide and pomalidomide, their immunomodulatory and tumoricidal effects, their mechanisms of action, as well as the influence of dexamethasone on their effect and pharmacological resistance. In conclusion, lenalidomide and pomalidomide demonstrate a powerful activity and they are highly effective and well-tolerated treatment options for patients with myeloma, used alone or in combination with dexamethasone.

Keywords : Dexamethasone; Multiple Myeloma; Neoplasm: Immunomodulation.

        · text in Spanish     · Spanish ( pdf )